Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
Ellen M. Apperloo(Dialyse Centrum Groningen), Hiddo J.L. Heerspink(University Medical Center Groningen), Deepak L. Bhatt(Mount Sinai Hospital), Brendon L. Neuen(The George Institute for Global Health), Robert A. Fletcher(UNSW Sydney), Niels Jongs(University Medical Center Groningen), John J.V. McMurray(University of Glasgow), Natalie Staplin(University of Oxford), David Z.I. Cherney(University Health Network), Marc S. Sabatine(Brigham and Women's Hospital), Christoph Wanner(Universitätsklinikum Würzburg), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Milton Packer(Baylor University Medical Center), Scott D. Solomon(Brigham and Women's Hospital), Muthiah Vaduganathan(Brigham and Women's Hospital), David C. Wheeler(University College London), Darren K. McGuire(Parkland Health & Hospital System), Michael Szarek(St. Michael's Hospital), Bruce Neal(UNSW Sydney), William G. Herrington(Oxford Health NHS Foundation Trust), Chih‐Chin Liu, Stephen D. Wiviott(Thrombolysis in Myocardial Infarction Study Group), Meg Jardine(Royal North Shore Hospital), Vlado Perkovic(University of Copenhagen), Faïez Zannad(Inserm), Stefan D. Anker(Bayer (Germany)), Javed Butler(Jackson Memorial Hospital), Silvio E. Inzucchi(Yale University)
Cited by 135
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.1k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k